Company news

Bluenergies Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

BELLUS Health announces a $17 million strategic partnership and financing with Pharmascience Inc.

April 5, 2012

BELLUS Health reports results for year ended December 31, 2011, and provides update on KIACTA(tm) phase 3 confirmatory study

February 22, 2012

BELLUS Health and Integris Pharma Ltd. enter into exclusive license agreement for VIVIMIND(tm) in Greece and Cyprus

December 1, 2011

OVOS Natural Health Inc. launches VIVIMIND(tm) in Canada

November 28, 2011

BELLUS Health reports results for third quarter ended September 30, 2011, and provides update on VIVIMIND(tm) partnerships

November 9, 2011

BELLUS Health reports results for second quarter ended June 30, 2011

August 10, 2011

Crystal Research Associates Issues Research Report on BELLUS Health Inc.

July 13, 2011

BELLUS health reports results for first quarter ended March 31, 2011

June 8, 2011

BELLUS health delivering on key strategic partnerships and KIACTA(tm) phase III development

May 11, 2011

BELLUS health issues shares in final payment for the exercise of its lease termination option

April 7, 2011

BELLUS health and the agahan group enter into broad license for VIVIMIND(tm) in the Middle East

April 4, 2011

BELLUS health completes restructuring initiatives with repatriation of intellectual property to canada

March 31, 2011

BELLUS health reports results for fourth quarter and year ended December 31, 2010

February 23, 2011

BELLUS health announces phase i results of prodrug NRM8499 intended for the treatment of Alzheimer's disease

January 31, 2011

BELLUS health exercises option to terminate lease

January 14, 2011

Advanced orthomolecular research acquires BELLUS health's Canadian subsidiary OVOS natural health

January 4, 2011

Crystal Research Associates Issues Updated Report on BELLUS Health Inc.

December 16, 2010

Celtic Therapeutics and BELLUS health initiate confirmatory phase III clinical study for KIACTA?, a drug candidate for the treatment of AA amyloidosis

December 15, 2010

BELLUS health reports results for third quarter ended September 30, 2010 and announces receipt of US$5 million from partner celtic therapeutics

November 10, 2010

BELLUS health and FB health enter agreement for BELLUS' VIVIMIND¿ in Italy

October 19, 2010

BELLUS health announces appointment of Martin Tolar, m.d., ph.d. to its board of directors

October 6, 2010

Health Canada grants VIVIMIND¿ a natural health product number

September 30, 2010

Bellus Health reports results for second quarter ended June 30, 2010

August 9, 2010

BELLUS Health Inc.

May 12, 2010

Annual Meeting of Shareholders - BELLUS Health provides update on corporate and product developments

May 12, 2010

BELLUS Health reports results for first quarter ended March 31, 2010

May 12, 2010

BELLUS Health Inc. Annual and Special Meeting of Shareholders May 12, 2010

May 12, 2010

BELLUS Health Inc. Annual and Special Meeting of Shareholders May 12, 2010

May 11, 2010

BELLUS Health ends NC-503 diabetes development program following results

May 4, 2010

BELLUS Health and Celtic Therapeutics enter agreement for BELLUS' drug candidate KIACTA(TM)

April 29, 2010

BELLUS Health announces launch of NRM8499 Phase I clinical study for the treatment of Alzheimer's disease

April 1, 2010

BELLUS Santé annonce le début de l'essai clinique de phase I sur le NRM8499 pour le traitement de la maladie d'Alzheimer

April 1, 2010

BELLUS Health reports results for fourth quarter and year ended December 31, 2009

February 24, 2010

BELLUS Santé annonce ses résultats pour le quatrième trimestre et l'exercice terminés le 31 décembre 2009

February 24, 2010

Roberto Bellini appointed President and CEO of BELLUS Health - Francesco Bellini to remain as Chairman of the Board; Charles Cavell appointed Deputy Chairman of the Board

December 15, 2009

Roberto Bellini nommé Président et chef de la direction de BELLUS Santé - Francesco Bellini demeure président du conseil; Charles Cavell nommé vice-président du conseil

December 15, 2009

BELLUS Santé annonce ses résultats pour le troisieme trimestre de 2009

November 10, 2009

BELLUS Health reports results for third quarter of fiscal 2009

November 10, 2009

TSX Delisting Review - BELLUS Health Inc. (BLU)

October 21, 2009

BELLUS Health announces results of rights offering

September 8, 2009

BayStreet.ca Research Alert: BELLUS Health Inc.

August 20, 2009

BELLUS Health reports results for first half of fiscal 2009

August 11, 2009

VIVIMIND(TM) granted certificate of free sale as food supplement in Italy - Premarket notification filed in the U.S.

July 16, 2009

BELLUS Health Inc. Announces Record Date for $12 Million Rights Offering To Common Shareholders

July 15, 2009

BELLUS Health Inc. Announces $12 Million Rights Offering To Common Shareholders

July 7, 2009

BELLUS Sante annonce que les resultats exploratoires publies dans une revue revisee par des pairs revelent que le tramiprosate ralentit l'atrophie de l'hippocampe cerebral et presentent des preuves preliminaires d'effets benefiques sur la cognition

July 6, 2009

BELLUS Health Announces Exploratory Results in Peer-Reviewed Publication Reveal Tramiprosate Slows Atrophy of Brain Hippocampus with Preliminary Evidence of Beneficial Effect on Cognition

July 6, 2009

FMRC Family Trust completes reorganization of itsholdings of securities of Bellus Health Inc.

June 25, 2009

BELLUS Sante inc. annonce la nomination d'un dirigeant

June 5, 2009

BELLUS Health Inc. Announces Officer

June 5, 2009

← Newer news releases · Older news releases →

Decks